Inducing Synthetic Lethality by Targeting DNA Repair

75 concepts46 papers1 proposal

Imagine a table supported by four legs. If you saw off one leg, the table remains standing, relying on the remaining three. If you saw off two adjacent legs, however, the table collapses.

This simple structural redundancy is the core intuition behind synthetic lethality in cancer biology. Cells have evolved redundant, overlapping pathways to perform vital functions like DNA repair. If a cancer cell loses one pathway due to an inherent genetic mutation, it survives by becoming entirely dependent on a backup pathway. Normal cells retain both options. By pharmacologically blocking that specific backup pathway, we can selectively collapse the cancer cell while leaving healthy cells completely unharmed.

Historically, exploiting this vulnerability required finding tumors with obvious, inherited genetic defects, such as BRCA1 or BRCA2 mutations. However, recent research has expanded this paradigm in two profound ways: first, by learning to read the subtle genomic "scars" of repair deficiencies even when classic mutations are missing; and second, by using drugs to artificially induce these vulnerabilities in previously resistant cells.


Reading the Genomic Scars of Inherent Deficiencies

The classic example of synthetic lethality involves targeting Homologous Recombination (HR)—a high-fidelity mechanism cells use to repair double-strand DNA breaks. When a tumor loses HR capability, it turns to error-prone backup mechanisms to survive. This state of deficiency is often called BRCAness.

As explained by Xiaoyu Li et al. in Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer, blocking these backup pathways with Poly(ADP-ribose) polymerase (PARP) inhibitors forces the accumulation of catastrophic DNA damage, leading to selective cell death. This therapeutic principle is further evaluated in clinical combinations by Suyue Zhao et al. in The efficacy and adverse effects of PARP inhibitor combined with chemotherapy compared with chemotherapy alone in the treatment of cancer patient.

But how do we identify these vulnerabilities if a tumor lacks a classic BRCA1/2 mutation?

When a specific DNA repair pathway fails, the error-prone backups leave predictable, distinct patterns of mutations, insertions, and deletions across the genome. Think of these as genomic "scars." Through mutational signature analysis, scientists can detect functional repair deficiencies by looking for these fingerprints rather than the upstream mutations themselves.

[Intact Repair Pathways]  ---> Normal Survival
[Inherent Mutation]       ---> Error-Prone Backup ---> Leaves "Genomic Scar" (e.g., Signature 3)
[Pharmacological Block]   ---> Backup Disabled   ---> Selective Cell Death (Synthetic Lethality)

In Defective homologous recombination DNA repair as therapeutic target in advanced chordoma, Stefan Gröschel et al. demonstrated that advanced chordomas—rare bone tumors lacking classic BRCA mutations—frequently exhibit a genomic fingerprint known as "Signature 3." This signature serves as a functional readout of homologous recombination deficiency (HRD), proving that these tumors are highly vulnerable to PARP inhibitors.

Similarly, Gregor Warsow et al. discovered in Genomic features of renal cell carcinoma with venous tumor thrombus that aggressive kidney cancers often display clear BRCAness signatures, expanding the potential patient pool for DNA repair therapies.

Furthermore, the authors of Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance showed that mutations in alternative genes like PALB2 generate the exact same Signature 3 readout, validating its use as a universal biomarker for DNA repair vulnerability. To map how these vulnerabilities manifest across different patient demographics, Changye Zou tracked age-dependent variations in Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients, uncovering significantly higher rates of HRD in pediatric cohorts.


Engineering Vulnerability: Induced Synthetic Lethality

What if a tumor's DNA repair pathways are perfectly intact? Instead of waiting for nature to mutate a cancer cell, researchers have figured out how to force a repair-proficient cell into a vulnerable state using a primary drug, setting it up for a fatal blow from a secondary drug. This strategy is known as induced synthetic lethality or "chemical BRCAness."

[Proficient Cell] + [Pathway Inhibitor] ---> [Transient Deficient State] + [PARP Inhibitor] ---> Lethal Catastrophe

Consider a glioblastoma tumor that naturally resists PARP inhibitors because its homologous recombination machinery is fully functional. In BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair, Shaolu Zhang et al. demonstrated that administering a PI3K inhibitor downregulates essential HR repair proteins like BRCA1 and RAD51. This pharmacological intervention temporarily strips the cancer cells of their primary defense, rendering them highly sensitive to the PARP inhibitor rucaparib.

This concept of engineering a transient deficiency appears across multiple cancer types:


Beyond DNA Repair: Metabolic and Alternative Dependencies

The logic of synthetic lethality is not confined to the classic BRCA-PARP axis. It applies broadly to any scenario where a tumor develops a "pathway addiction" to survive high genomic or metabolic stress.

For instance, highly unstable cancer cells frequently rely on error-prone backup DNA polymerases to bypass lesions during replication. In Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma, Qun Li et al. targeted DNA polymerase theta (Polθ). Inhibiting this specific backup mechanism creates a synthetic lethal effect when paired with DNA-damaging agents, destroying myeloma cells while sparing healthy tissue that relies on high-fidelity repair.

                          ┌───> High-Fidelity Repair (Normal Cells)
[Genomic Instability] ────┤
                          └───> Polθ Backup Pathway (Addicted Cancer Cells) ───x [Polθ Inhibitor] = Death

This framework also bridges the gap between tumor metabolism and cellular maintenance. In Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment, Congwang Zhang et al. detailed how deficiencies in metabolic Krebs cycle enzymes, such as fumarate hydratase, cause an accumulation of intracellular metabolites that directly suppress double-strand break repair. This creates an inherent, metabolism-linked synthetic lethality that can be targeted therapeutically.

Finally, functional genomics screens continue to uncover unexpected survival dependencies tied to specific oncogenic losses:

By mapping these hidden networks of cellular reliance—whether inherent, metabolic, or chemically engineered—oncologists are moving away from broad, toxic chemotherapies toward a strategy of elegant, mathematically certain destruction.

History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_synthetic_lethality_25d8776a,
  title = {synthetic lethality},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/synthetic-lethality/rdr_25d8776aabf0405e95eebc9f76b8e824},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_synthetic_lethality_25d8776a_v1,
  title = {synthetic lethality},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/synthetic-lethality/rdr_25d8776aabf0405e95eebc9f76b8e824/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake